Atlas Trials

Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer

Clinical trial NCT03450330 · COMPLETED

Trial details

NCT number
NCT03450330
Sponsor
Dizal Pharmaceuticals
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Nonsmall Cell Lung Cancer
Start date
2018-04-16
Primary completion
2019-09-03
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.